Abstracts tagged "Biomarkers"

Abstract Number: 0256 • ACR Convergence 2022
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
Kevin Cunningham¹, Benjamin Hur², John Davis² and Jaeyun Sung², ¹University of Minnesota, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: RA is commonly diagnosed through a serological test for the presence of ACPA, and RA patients who test positive are collectively known as 'ACPA-positive…
Abstract Number: 0531 • ACR Convergence 2022
Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood
Espen Riskedal¹, Karl Trygve Kalleberg¹, Arne Søraas², Maria Dahl Mjaavatten³, Grethe-Elisabeth Stenvik⁴, Joe Sexton⁴, Janis Neumann¹, Cathrine Lund Hadley¹, Guro Goll⁴, Silje Watterdal Syversen⁴, Håkon Bøås⁵, Jennifer Ruth Harris⁵, Astanand Jugessur⁵, Siri Lillegraven⁴ and Espen Haavardsholm⁴, ¹Age Labs AS, Oslo, Oslo, Norway, ²Age Labs AS, Eiksmarka, Norway, ³Diakonhjemmet Hospital, Haslum, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: Patients with seronegative rheumatoid arthritis (RA) exhibit no detectable antibodies, often resulting in delayed diagnosis and treatment initiation. A blood-based test, capable of detecting…
Abstract Number: 0655 • ACR Convergence 2022
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
Alessandra Ida Celia¹, Jeffery Hodgin², Avi Rosenberg³, Laurence S Magder⁴, Jill Buyon⁵, Betty Diamond⁶, Judith James⁷, William Apruzzese⁸, Paride Fenaroli⁹, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter izmirly¹⁰, Michael Belmont⁵, Anne Davidson⁶, Daniel W. Goldman¹¹, the Accelerating Medicines Partnership (AMP) RA/SLE¹², Michelle Petri¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Michigan, Ann Arbor, MI, ³Johns Hopkins University, Ballwin, MO, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, ¹⁰NYU Long Island School of Medicine, New York, NY, ¹¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹²Multiple Insitutions
Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
Abstract Number: 0919 • ACR Convergence 2022
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
Siddharth Jain¹, Varun Dhir², Amita Aggarwal³, Ranjan Gupta⁴, Bidya Laishangtham¹, Aastha Khullar¹, Shankar Naidu¹, Veena Dhawan¹, Shefali Sharma⁵, Aman Sharma⁶ and sanjay jain¹, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴All India Institute of Medical Sciences, New Delhi, India, ⁵PGIMER< Chandigarh, Chandigarh, India, ⁶PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX) is the gold standard, first-line therapy for rheumatoid arthritis (RA). However, not all patients respond to MTX, and the predictors of its…
Abstract Number: 1155 • ACR Convergence 2022
Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
Elena Carnero-Montoro¹, Ivan Arias-de la Rosa², Clementina Lopez-Medina³, lourdes Ladehesa-Pineda⁴, Rafaela Ortega-Castro², Daniel Toro-Domínguez¹, Manuel Martinez-Bueno¹, Raúl López-Domínguez⁵, Olivia Castellini-Pérez¹, Guillermo Barturen¹, Nuria Barbarroja², Eduardo Collantes² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ³Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁴Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁵University of Granada, Granada, Spain
Background/Purpose: An important role of DNA methylation changes in Spondylitis Ankylosing has been recently demonstrated by epigenome-wide studies. However, there is a lack of genome-wide…
Abstract Number: 1478 • ACR Convergence 2022
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung¹, Cherie Ng¹, AMP SLE/RA consortium⁵, Michelle Petri⁶, Chandra Mohan⁷ and Chaim Putterman⁸, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Accelerating Medicines Partnership, Los Angeles, CA, ⁶Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁷University of Houston, Houston, TX, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…
Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose felix Restrepo Suarez¹, Inmaculada Del Rincon¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science center at San Antonio, San Antonio, TX, ²University of Texas Health Sciences Center San Antonio, San antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…
Abstract Number: 1874 • ACR Convergence 2022
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Sarah Tansley¹, Caroline Cotton², Fionnuala McMorrow¹, Hui Lu¹, Aravinthan Loganathan¹, Zoe Betteridge¹, Robert New³, Lisa Spencer⁴, Neil McHugh¹ and Robert Cooper⁴, ¹University of Bath, Bath, United Kingdom, ²Liverpool University Hospital, Liverpool, United Kingdom, ³NCA, Manchester, ⁴University of Liverpool, Liverpool
Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…
Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 2234 • ACR Convergence 2022
Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Joshua Baker¹, Kristin Wipfler², Marianna Olave³, Sofia Pedro⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵UCSF, San Rafael, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Obesity has been linked to chronic pain and pain sensitization in the general population and among patients with rheumatoid arthritis (RA). The mechanism by…
Abstract Number: 0023 • ACR Convergence 2022
New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature
Maxime Auroux¹, Marjorie Millet², Blandine Merle², Elisabeth Fontanges¹, Florence Duvert¹, Evelyne Gineyts³, Jean-Charles Rousseau³, Olivier Borel², Alexandre Mercier¹, Eric LESPESSAILLES⁴ and Roland Chapurlat¹, ¹Hospices Civils de Lyon, LYON, France, ²INSERM U1033, LYON, France, ³INSERM 1033, Lyon, France, ⁴Regional hospital centre of Orleans, France, ORLEANS, Centre, France
Background/Purpose: Hand osteoarthritis (HOA) is a highly prevalent disease, associated with important disability and socio-economic burden. Erosive HOA, almost exclusively found in women, induces more…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 0656 • ACR Convergence 2022
Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Ying Chen², Xinzhuang Yang³, Qian Wang⁴, JIULIANG ZHAO⁵, Xiaoyue Deng¹, Shengjie Li³, Yongtai Liu⁶, Zhuang Tian⁶, Juan Shen², Qijun Liao², Yanhong Wang⁷, Xianbo Zuo⁸, Xuejun Zhang⁹, MENGTAO LI¹, Yong Cui⁸, Xueqing Yu¹⁰ and Xiaofeng Zeng¹¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ²BGI-Shenzhen, Shenzhen, China, ³Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China, ⁵Beijing Union Medical College Hospital, Beijing, China, ⁶Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁷Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁸Department of Dermatology, China-Japan Friendship Hospital, Beijing, China, ⁹Institute of Dermatology, Anhui Medical University, Hefei, China, ¹⁰Division of Nephrology, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, ¹¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare and severe complication of systemic lupus erythematosus (SLE). Human leucocyte antigen (HLA) gene variants in the major…
Abstract Number: 0933 • ACR Convergence 2022
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Ana Triguero¹, JUAN BALDIVIESO ACHA², Emilia Roy Vallejo³, Patricia Quiroga-Colina⁴, Irene Maria Llorente Cubas², Rosario Garcia-Vicuña⁵, amaya Puig kröger⁶ and Isidoro Gonzalez², ¹Hospital Universitario La Princesa, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Spain, ³Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Laboratory of Immunometabolism, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: We recently described that methotrexate (MTX) could exert its immunomodulatory effect through the induction of A20 expression , a protein that negatively regulates NFkB…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].